Brief: Stayble Reports Top-Line Data From Phase IIb Study On Back Pain Drug

Stayble Therapeutics AB

09/11/2023 07:08

Nov 9 (Reuters) - Stayble Therapeutics AB  STABL.ST :
    * REPORTS TOP-LINE DATA FROM PHASE IIB STUDY
    * RANDOMIZED, DOUBLE-BLIND STUDY DID NOT ACHIEVE THE PRIMARY
OBJECTIVE
    * TODAY PRESENTS TOP-LINE DATA FROM THE COMPANY'S PHASE IIB
STUDY
WITH STA363 AGAINST CHRONIC DISC-RELATED BACK PAIN (DEGENERATIVE
DISC DISEASE, "DDD")
    * TREATMENT WITH STA363 DID NOT SHOW A BETTER EFFECT
REGARDING
PAIN REDUCTION THAN WITH PLACEBO. HOWEVER; ALL THREE GROUPS
SHOWED A SIGNIFICANT PAIN REDUCTION AFTER TREATMENT

Source text for Eikon:  ID:nWkrbnSgnJ 
Further company coverage:  STABL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))